Lansdowne Partners (UK)’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-35,000
| Closed | -$1.46M | – | 23 |
|
|
2024
Q4 | $1.46M | Buy |
+35,000
| New | +$1.46M | 0.11% | 17 |
|
|
2024
Q3 | – | Sell |
-20,500
| Closed | -$2.43M | – | 28 |
|
|
2024
Q2 | $2.43M | Sell |
20,500
-15,500
| -43% | -$1.84M | 0.19% | 15 |
|
|
2024
Q1 | $3.84M | Sell |
36,000
-33,000
| -48% | -$3.52M | 0.25% | 15 |
|
|
2023
Q4 | $6.86M | Buy |
69,000
+11,000
| +19% | +$1.09M | 0.5% | 16 |
|
|
2023
Q3 | $5.99M | Buy |
58,000
+22,500
| +63% | +$2.32M | 0.55% | 15 |
|
|
2023
Q2 | $4.31M | Sell |
35,500
-2,000
| -5% | -$243K | 0.48% | 14 |
|
|
2023
Q1 | $5.76M | Buy |
37,500
+1,500
| +4% | +$230K | 0.89% | 12 |
|
|
2022
Q4 | $6.47M | Buy |
36,000
+7,250
| +25% | +$1.3M | 1.34% | 8 |
|
|
2022
Q3 | $3.4M | Sell |
28,750
-16,750
| -37% | -$1.98M | 0.73% | 11 |
|
|
2022
Q2 | $6.5M | Buy |
45,500
+14,500
| +47% | +$2.07M | 0.92% | 13 |
|
|
2022
Q1 | $5.34M | Buy |
+31,000
| New | +$5.34M | 0.44% | 18 |
|